As compared to patients who received angiotensin-II stimulating antihypertensive drugs, those who received angiotensin-II inhibiting drugs were significantly more likely to develop AD (adjusted hazard ratio: 1.15, 95% CI: 1.01–1.32), vascular dementia (1.27, 1.06–1.53), MCI (1.27, 1.02–1.59), other dementia (1.22, 1.15–1.30), and total ADRD (1.21, 1.14–1.28), but had no significantly different risk of DLB and FTD. The gene discussed is AGT; the disease is Lewy body dementia.